home / stock / brrgf / brrgf quote
Last: | $0.025 |
---|---|
Change Percent: | 0.0% |
Open: | $0.025 |
Close: | $0.025 |
High: | $0.025 |
Low: | $0.025 |
Volume: | 37,305 |
Last Trade Date Time: | 11/29/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.025 | $0.025 | $0.025 | $0.025 | $0.025 | 37,305 | 11-29-2023 |
$1.77 | $1.77 | $1.77 | $1.77 | $1.77 | 100 | 01-04-2022 |
$2.11 | $2.11 | $2.11 | $2.11 | $2.11 | 100 | 11-19-2021 |
$2.14 | $2.14 | $2.14 | $2.14 | $2.14 | 400 | 11-17-2021 |
$2.31 | $2.31 | $2.31 | $2.31 | $2.31 | 100 | 10-11-2021 |
$3.5 | $3.52 | $3.5 | $3.52 | $3.5 | 400 | 06-08-2021 |
$3.52 | $3.52 | $3.52 | $3.52 | $3.52 | 2,840 | 04-30-2021 |
$3.52 | $3.52 | $3.52 | $3.52 | $3.52 | 500 | 03-03-2021 |
$3.88 | $3.88 | $3.88 | $3.88 | $3.88 | 2,650 | 02-22-2021 |
$3.85 | $3.85 | $3.85 | $3.85 | $3.85 | 500 | 02-19-2021 |
$4 | $4 | $4 | $4 | $4 | 1,295 | 02-17-2021 |
$3.94 | $3.94 | $3.94 | $3.94 | $3.94 | 100 | 12-17-2020 |
$3.72 | $3.72 | $3.72 | $3.72 | $3.72 | 3,700 | 12-10-2020 |
$3.72 | $3.72 | $3.72 | $3.72 | $3.72 | 3,000 | 12-09-2020 |
$3.7456 | $3.7456 | $3.7456 | $3.7456 | $3.7456 | 350 | 12-08-2020 |
$2.95 | $3 | $2.95 | $3 | $2.95 | 200 | 10-16-2020 |
$3.8 | $3.8 | $3.8 | $3.8 | $3.8 | 400 | 09-02-2020 |
$3.8 | $3.8 | $3.8 | $3.8 | $3.8 | 1,200 | 08-31-2020 |
$3.8 | $3.8 | $3.8 | $3.8 | $3.8 | 1,300 | 08-27-2020 |
$3.69 | $3.69 | $3.69 | $3.69 | $3.69 | 100 | 08-24-2020 |
News, Short Squeeze, Breakout and More Instantly...
Brent Resources Group Ltd Company Name:
BRRGF Stock Symbol:
OTCMKTS Market:
Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients PR Newswire BERGEN, Norway ...
BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020 BERGEN, Norway , Dec. 6, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL...
BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting PR Newswire BERGEN, Norway, Nov. 11, 2020 BERGEN, Norway , Nov. 11, 2020 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing...